64221-86-9C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCN=CN)C[C@H]12ZSKVGTPCRGIANV-ZXFLCMHBSA-NImipenem is a broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup. It has a role as an antibacterial drug. It is a member of carbapenems and a beta-lactam antibiotic allergen. It is a tautomer of an imipenem zwitterion.
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Antibiotics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to pencillin binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This preferential binding to PBP-2 and PBP-1b results in the direct conversion of the individual cell to a spheroblast, which leads to rapid cell lysis and death without filament formation.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Imipenem
DILI Positive
Intravenous
DOI:10.1016/j.drudis.2019.09.022
Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including <i>Pseudomonas aeruginosa</i> and the <i>Enterococcus</i>. It exerts a bactericidal effects by disrupting cell wall synthesis.
Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to penicillin-binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This inhibition of PBPs prevents the bacterial cell from adding to the peptidoglycan polymer which forms the bacterial cell wall eventually leading to cell death.
Imipenem is metabolized by renal dehydropeptidase.
Renal. Half Life: 1 hour
Q20IM7HE75
IMIPENEM ANHYDROUS
Chemical Structure [CS] - Carbapenems
Established Pharmacologic Class [EPC] - Penem Antibacterial
Imipenem anhydrous is a Penem Antibacterial.
Wird geladen…
64221-86-9、74431-23-5DTXSID2023143CHEMBL148、CHEMBL43708CHEBI:471744Imipenem is not effectively absorbed from the gastrointestinal tract and therefore must be administered parenterally. The bioavailability of the IM injection is 89%.
Approximately 70% of imipenem is excreted in the urine as the parent drug.
The reported volume of distribution for imipenem ranges from 0.23-0.31 L/kg.
The total clearance of imipenem is 0.2 L/h/kg. When used alone, the renal clearance is 0.05 L/h/kg. In combination with cilastatin the renal clearance of imipenem is 0.15 L/h/kg, likely due to the increased concentration of the parent drug.
Use (kg) in Switzerland (2009): >100
For the treatment of bacterial infections caused by susceptible bacteria.
BeschreibungImipenem is a chemically stable thienamycin derivative with an antibacterial activity that is broader in spectrum and of greater potency than most of the third generation cephalosporins. Combination with cilastatin, an inhibitor of renal brush-border dehydropeptidase-I, increases both urinary and plasma levels of imipenem.
VerwendenCarbapenem antibacterial.